Therapeutic impact of human serum albumin-thioredoxin fusion protein on influenza virus-induced lung injury mice

Ryota Tanaka, Yu Ishima, Yuki Enoki, Kazuhiko Kimachi, Tatsuya Shirai, Hiroshi Watanabe, Victor T.G. Chuang, Toru Maruyama, Masaki Otagiri

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Reactive oxygen species (ROS) are the primary pathogenic molecules produced in viral lung infections. We previously reported on the use of a recombinant human serum albumin (HSA)-thioredoxin 1 (Trx) fusion protein (HSA-Trx) for extending the half-life Trx, an endogenous protein with anti-oxidant properties. As a result, it was possible to overcome the unfavorable pharmacokinetic and short pharmacological properties of Trx. We hypothesized that HSA-Trx would attenuate the enhanced ROS production of species such as hydroxyl radicals by neutrophils during an influenza viral infection. The levels of 8-hydroxy-2'-deoxyguanosine and 3-nitrotyrosine were used as indices of the anti-oxidant activity of HSA-Trx. In addition, the cytoprotective effects of HSA-Trx were examined in PR8 (H1N1) influenza virus-induced lung injured mice. The findings show that HSA-Trx reduced the number of total cells, neutrophils, and total protein in BALF of influenza virus-induced lung injured mice. The HSA-Trx treatment significantly decreased the level of 8-hydroxy-2'-deoxyguanosine and 3-nitrotyrosine, but failed to inhibit inducible nitric oxide synthase expression, in the lungs of the virus-infected mice. On the other hand, Tamiflu® treatment also significantly suppressed the production of inflammatory cells and neutrophil infiltration, as well as the protein level in BALF and lung histopathological alterations caused by the influenza virus. The suppressive effect of Tamiflu® was slightly stronger than that of HSA-Trx. Interestingly, Tamiflu® significantly decreased virus proliferation, while HSA-Trx had no effect. These results indicate that HSA-Trx may be of therapeutic value for the treatment of various acute inflammatory disorders such as influenza-virus-induced pneumonia, by inhibiting inflammatory-cell responses and suppressing the overproduction of NO in the lung.

Original languageEnglish
Article number561
JournalFrontiers in Immunology
Volume5
Issue numberNOV
DOIs
Publication statusPublished - 2014 Jan 1

Keywords

  • Albumin
  • Anti-oxidization
  • Fusion
  • Influenza virus
  • Thioredoxin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Therapeutic impact of human serum albumin-thioredoxin fusion protein on influenza virus-induced lung injury mice'. Together they form a unique fingerprint.

  • Cite this

    Tanaka, R., Ishima, Y., Enoki, Y., Kimachi, K., Shirai, T., Watanabe, H., Chuang, V. T. G., Maruyama, T., & Otagiri, M. (2014). Therapeutic impact of human serum albumin-thioredoxin fusion protein on influenza virus-induced lung injury mice. Frontiers in Immunology, 5(NOV), [561]. https://doi.org/10.3389/fimmu.2014.00561